

# John Pickup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4489563/publications.pdf>

Version: 2024-02-01

56  
papers

7,888  
citations

156536

32  
h-index

182931

54  
g-index

59  
all docs

59  
docs citations

59  
times ranked

7940  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report. Journal of Diabetes Science and Technology, 2022, 16, 775-782.	1.3	3
2	Diabetes Technology Meeting 2021. Journal of Diabetes Science and Technology, 2022, , 193229682210902.	1.3	2
3	Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology, 2021, 15, 916-960.	1.3	1
4	Is insulin pump therapy effective in Type 1 diabetes?. Diabetic Medicine, 2019, 36, 269-278.	1.2	54
5	The Prospective Association Between Inflammation and Depressive Symptoms in Type 2 Diabetes Stratified by Sex. Diabetes Care, 2019, 42, 1865-1872.	4.3	9
6	A modelling study of the budget impact of improved glycaemic control in adults with Type 1 diabetes in the UK. Diabetic Medicine, 2019, 36, 988-994.	1.2	8
7	Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care, 2017, 40, 715-722.	4.3	70
8	Real-Time Continuous Glucose Monitoring in Type 1 Diabetes: A Qualitative Framework Analysis of Patient Narratives. Diabetes Care, 2015, 38, 544-550.	4.3	145
9	Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review. Diabetic Medicine, 2015, 32, 1415-1424.	1.2	58
10	Insulin Pumps. Diabetes Technology and Therapeutics, 2015, 17, S-21-S-26.	2.4	2
11	Banting Memorial Lecture 2014 Technology and diabetes care: appropriate and personalized. Diabetic Medicine, 2015, 32, 3-13.	1.2	18
12	Insulin Pumps. Diabetes Technology and Therapeutics, 2015, 17, S-21-S-26.	2.4	2
13	Variations in the quality and sustainability of long-term glycaemic control with continuous subcutaneous insulin infusion. Diabetic Medicine, 2014, 31, 1174-1177.	1.2	30
14	Insulin Pumps. Diabetes Technology and Therapeutics, 2014, 16, S-17-S-22.	2.4	10
15	Insulin Pumps. Diabetes Technology and Therapeutics, 2013, 15, S-24-S-28.	2.4	4
16	Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 4160-4162.	4.3	139
17	Innate immunity, insulin resistance and type 2 diabetes. Diabetologia, 2012, 55, 273-278.	2.9	92
18	Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ: British Medical Journal, 2011, 343, d3805-d3805.	2.4	442

#	ARTICLE	IF	CITATIONS
19	NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. <i>Diabetic Medicine</i> , 2009, 26, 1-4.	1.2	33
20	Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS). <i>Diabetologia</i> , 2008, 51, 493-501.	2.9	25
21	Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. <i>Diabetic Medicine</i> , 2008, 25, 765-774.	1.2	550
22	Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, S140-S145.	4.3	93
23	Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes. <i>Diabetes Care</i> , 2006, 29, 1449-1452.	4.3	33
24	Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 813-823.	4.3	1,171
25	Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2003, 20, 723-726.	1.2	43
26	Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. <i>Diabetic Medicine</i> , 2003, 20, 1012-1015.	1.2	123
27	Continuous Subcutaneous Insulin Infusion at 25 Years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. <i>Diabetes Care</i> , 2002, 25, 593-598.	4.3	362
28	Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2002, 324, 705-705.	2.4	413
29	Continuous subcutaneous insulin infusion in type 1 diabetes. <i>BMJ: British Medical Journal</i> , 2001, 322, 1262-1263.	2.4	25
30	Sensing metabolites using donor-acceptor nanodistributions in fluorescence resonance energy transfer. <i>Applied Physics Letters</i> , 2001, 78, 2796-2798.	1.5	15
31	The innate immune response and type 2 diabetes: evidence that leptin is associated with a stress-related (acute-phase) reaction. <i>Clinical Endocrinology</i> , 2000, 52, 107-112.	1.2	36
32	Plasma interleukin-6, tumour necrosis factor $\alpha$ and blood cytokine production in type 2 diabetes. <i>Life Sciences</i> , 2000, 67, 291-300.	2.0	476
33	Is Type II diabetes mellitus a disease of the innate immune system?. <i>Diabetologia</i> , 1998, 41, 1241-1248.	2.9	892
34	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. <i>Diabetologia</i> , 1997, 40, 1286-1292.	2.9	1,108
35	Serum Sialic Acid Concentration and Coronary Heart Disease in NIDDM. <i>Diabetes Care</i> , 1995, 18, 1100-1103.	4.3	53
36	Plasma sialic acid in animal models of diabetes mellitus: Evidence for modulation of sialic acid concentrations by insulin deficiency. <i>Life Sciences</i> , 1995, 57, 1383-1391.	2.0	27

#	ARTICLE	IF	CITATIONS
37	Responses and calibration of amperometric glucose sensors implanted in the subcutaneous tissue of man. <i>Acta Diabetologica</i> , 1993, 30, 143-148.	1.2	40
38	Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. <i>Clinica Chimica Acta</i> , 1993, 219, 131-138.	0.5	72
39	Sampling and sensing blood glucose. <i>Lancet, The</i> , 1993, 342, 1068.	6.3	6
40	In Vivo Glucose Monitoring: Sense and Sensorbility. <i>Diabetes Care</i> , 1993, 16, 535-539.	4.3	48
41	Blood Glucose and Glycated Haemoglobin Measurement in Hospital: Which Method?. <i>Diabetic Medicine</i> , 1993, 10, 402-411.	1.2	19
42	Clinicians' requirements for chemical sensors for in vivo monitoring: A multinational survey. <i>Biosensors and Bioelectronics</i> , 1991, 6, 639-646.	5.3	42
43	In vivo molecular sensing in diabetes mellitus: an implantable glucose sensor with direct electron transfer. <i>Diabetologia</i> , 1989, 32, 213-217.	2.9	105
44	Patterns of Hyperinsulinaemia in Type 1 Diabetic Patients With and Without Nephropathy. <i>Diabetic Medicine</i> , 1989, 6, 685-691.	1.2	17
45	Reply from Williamset al.. <i>Diabetic Medicine</i> , 1988, 5, 711-711.	1.2	0
46	Progress towards in vivo glucose sensing with a ferrocene-mediated amperometric enzyme electrode. <i>Hormone and Metabolic Research Supplement Series</i> , 1988, 20, 34-6.	0.2	2
47	Implantable glucose sensors: Choosing the appropriate sensing strategy. <i>Biosensors</i> , 1987, 3, 335-346.	2.0	25
48	Hypoglycemia and Counterregulation in Insulin-Dependent Diabetic Patients: A Comparison of Continuous Subcutaneous Insulin Infusion and Conventional Insulin Injection Therapy. <i>Diabetes Care</i> , 1986, 9, 221-227.	4.3	22
49	The Pump Life: Patient Responses and Clinical and Technological Problems. <i>Diabetes</i> , 1985, 34, 37-41.	0.3	17
50	Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. <i>Audit of medical care. American Journal of Medicine</i> , 1985, 79, 685-691.	0.6	67
51	Safety of continuous subcutaneous insulin infusion: Metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. <i>Diabetologia</i> , 1982, 22, 175-9.	2.9	44
52	Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption.. <i>BMJ: British Medical Journal</i> , 1981, 282, 347-350.	2.4	66
53	continuous Subcutaneous Insulin Infusion in the Treatment of Diabetes Mellitus. <i>Diabetes Care</i> , 1980, 3, 290-300.	4.3	118
54	LONG-TERM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN DIABETICS AT HOME. <i>Lancet, The</i> , 1979, 314, 870-873.	6.3	117

#	ARTICLE	IF	CITATIONS
55	Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.. BMJ: British Medical Journal, 1978, 1, 204-207.	2.4	493
56	Osmotic and Electrolytic Changes during an Oral Glucose Tolerance Test in Diabetics. Clinical Science and Molecular Medicine, 1978, 54, 23P-23P.	0.8	0